1	Serum	Serum	B-NP	NN	O	4	NMOD	-1
2	and	and	I-NP	CC	O	4	NMOD	-1
3	urine	urine	I-NP	NN	O	4	NMOD	-1
4	levels	level	I-NP	NNS	O	0	ROOT	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	interleukin-8	interleukin-8	B-NP	NN	B-protein	5	PMOD	-1
7	in	in	B-PP	IN	O	4	NMOD	-1
8	patients	patient	B-NP	NNS	O	7	PMOD	-1
9	with	with	B-PP	IN	O	8	NMOD	-1
10	non-Hodgkin	non-Hodgkin	B-NP	JJ	O	12	NMOD	-1
11	's	's	B-NP	POS	O	12	NMOD	-1
12	lymphoma	lymphoma	I-NP	NN	O	9	PMOD	-1
13	.	.	O	.	O	4	P	-1

1	Angiogenesis	Angiogenesis	B-NP	NN	O	2	SUB	3	Angiogenesis
2	plays	play	B-VP	VBZ	O	0	ROOT	-1
3	an	an	B-NP	DT	O	5	NMOD	-1
4	important	important	I-NP	JJ	O	5	NMOD	0
5	role	role	I-NP	NN	O	2	OBJ	0
6	in	in	B-PP	IN	O	2	VMOD	-1
7	many	many	B-NP	JJ	O	8	NMOD	-1
8	types	type	I-NP	NNS	O	6	PMOD	-1
9	of	of	B-PP	IN	O	8	NMOD	-1
10	cancer	cancer	B-NP	NN	O	9	PMOD	-1
11	.	.	O	.	O	2	P	-1

1	Interleukin-8	Interleukin-8	B-NP	NN	B-protein	5	SUB	-1
2	(	(	O	(	O	4	DEP	-1
3	IL-8	IL-8	B-NP	NN	B-protein	4	DEP	-1
4	)	)	O	)	O	1	NMOD	-1
5	is	be	B-VP	VBZ	O	0	ROOT	-1
6	known	know	I-VP	VBN	O	5	VC	-1
7	to	to	I-VP	TO	O	8	VMOD	-1
8	be	be	I-VP	VB	O	6	VMOD	-1
9	a	a	B-NP	DT	O	13	NMOD	-1
10	pro-inflammatory	pro-inflammatory	I-NP	JJ	B-protein	12	AMOD	-1
11	and	and	I-NP	CC	I-protein	12	AMOD	-1
12	pro-angiogenic	pro-angiogenic	I-NP	JJ	I-protein	13	NMOD	3	angiogenic
13	cytokine	cytokine	I-NP	NN	I-protein	17	SUB	-1
14	,	,	O	,	O	17	P	-1
15	and	and	O	CC	O	17	VMOD	-1
16	IL-8	IL-8	B-NP	NN	B-protein	17	SUB	-1
17	has	have	B-VP	VBZ	O	8	VMOD	-1
18	been	be	I-VP	VBN	O	17	VC	-1
19	reported	report	I-VP	VBN	O	18	VC	-1
20	to	to	I-VP	TO	O	21	VMOD	-1
21	be	be	I-VP	VB	O	19	VMOD	-1
22	associated	associate	I-VP	VBN	O	21	VC	16	associated
23	with	with	B-PP	IN	O	22	VMOD	-1
24	tumor	tumor	B-NP	NN	O	25	NMOD	-1
25	progression	progression	I-NP	NN	O	29	NMOD	2	progression
26	,	,	O	,	O	29	P	-1
27	prognosis	prognosis	B-NP	NN	O	29	NMOD	-1
28	and	and	I-NP	CC	O	29	NMOD	-1
29	survival	survival	I-NP	NN	O	23	PMOD	0
30	in	in	B-PP	IN	O	29	NMOD	-1
31	several	several	B-NP	JJ	O	32	NMOD	-1
32	types	type	I-NP	NNS	O	30	PMOD	-1
33	of	of	B-PP	IN	O	32	NMOD	-1
34	cancers	cancer	B-NP	NNS	O	33	PMOD	-1
35	.	.	O	.	O	5	P	-1

1	However	However	B-ADVP	RB	O	14	VMOD	-1
2	,	,	O	,	O	14	P	-1
3	the	the	B-NP	DT	O	4	NMOD	-1
4	role	role	I-NP	NN	O	14	SUB	16	role
5	of	of	B-PP	IN	O	4	NMOD	-1
6	IL-8	IL-8	B-NP	NN	B-protein	5	PMOD	-1
7	in	in	B-PP	IN	O	4	NMOD	-1
8	non-Hodgkin	non-Hodgkin	B-NP	JJ	O	10	NMOD	-1
9	's	's	B-NP	POS	O	10	NMOD	-1
10	lymphoma	lymphoma	I-NP	NN	O	7	PMOD	-1
11	(	(	O	(	O	13	DEP	-1
12	NHL	NHL	B-NP	NN	O	13	DEP	-1
13	)	)	O	)	O	10	NMOD	-1
14	has	have	B-VP	VBZ	O	0	ROOT	-1
15	not	not	I-VP	RB	O	14	VMOD	-1
16	been	be	I-VP	VBN	O	14	VC	-1
17	fully	fully	B-ADJP	RB	O	16	VMOD	-1
18	determined	determine	I-ADJP	VBN	O	16	VC	-1
19	.	.	O	.	O	14	P	-1

1	Here	Here	B-ADVP	RB	O	4	VMOD	-1
2	,	,	O	,	O	4	P	-1
3	we	we	B-NP	PRP	O	4	SUB	-1
4	evaluated	evaluate	B-VP	VBD	O	0	ROOT	-1
5	the	the	B-NP	DT	O	6	NMOD	-1
6	usefulness	usefulness	I-NP	NN	O	4	OBJ	-1
7	of	of	B-PP	IN	O	6	NMOD	-1
8	measuring	measure	B-VP	VBG	O	7	PMOD	-1
9	serum	serum	B-NP	NN	O	13	NMOD	-1
10	and	and	I-NP	CC	O	13	NMOD	-1
11	urine	urine	I-NP	NN	O	13	NMOD	-1
12	IL-8	IL-8	I-NP	NN	B-protein	13	NMOD	-1
13	levels	level	I-NP	NNS	O	8	OBJ	-1
14	in	in	B-PP	IN	O	8	VMOD	-1
15	patients	patient	B-NP	NNS	O	14	PMOD	-1
16	with	with	B-PP	IN	O	15	NMOD	-1
17	NHL	NHL	B-NP	NN	O	16	PMOD	-1
18	.	.	O	.	O	4	P	-1

1	We	We	B-NP	PRP	O	2	SUB	-1
2	developed	develop	B-VP	VBD	O	0	ROOT	0
3	reference	reference	B-NP	NN	O	4	NMOD	-1
4	intervals	interval	I-NP	NNS	O	2	OBJ	-1
5	for	for	B-PP	IN	O	4	NMOD	-1
6	serum	serum	B-NP	NN	O	10	NMOD	-1
7	and	and	I-NP	CC	O	10	NMOD	-1
8	urine	urine	I-NP	NN	O	10	NMOD	-1
9	IL-8	IL-8	I-NP	NN	B-protein	10	NMOD	-1
10	level	level	I-NP	NN	O	5	PMOD	-1
11	in	in	B-PP	IN	O	4	NMOD	-1
12	131	131	B-NP	CD	O	14	NMOD	-1
13	control	control	I-NP	NN	O	14	NMOD	0
14	individuals	individual	I-NP	NNS	O	11	PMOD	-1
15	.	.	O	.	O	2	P	-1

1	We	We	B-NP	PRP	O	2	SUB	-1
2	measured	measure	B-VP	VBD	O	16	VMOD	-1
3	serum	serum	B-NP	NN	O	4	NMOD	-1
4	IL-8	IL-8	I-NP	NN	B-protein	8	NMOD	-1
5	and	and	O	CC	O	7	NMOD	-1
6	urine	urine	B-NP	NN	O	7	NMOD	-1
7	IL-8	IL-8	I-NP	NN	B-protein	8	NMOD	-1
8	levels	level	I-NP	NNS	O	2	OBJ	-1
9	in	in	B-PP	IN	O	2	VMOD	-1
10	patients	patient	B-NP	NNS	O	9	PMOD	-1
11	with	with	B-PP	IN	O	10	NMOD	-1
12	NHL	NHL	B-NP	NN	O	11	PMOD	-1
13	,	,	O	,	O	16	P	-1
14	and	and	O	CC	O	16	VMOD	-1
15	we	we	B-NP	PRP	O	16	SUB	-1
16	compared	compare	B-VP	VBD	O	0	ROOT	-1
17	the	the	B-NP	DT	O	18	NMOD	-1
18	concentrations	concentration	I-NP	NNS	O	16	OBJ	-1
19	with	with	B-PP	IN	O	18	NMOD	-1
20	those	those	B-NP	DT	O	19	PMOD	-1
21	of	of	B-PP	IN	O	20	NMOD	-1
22	control	control	B-NP	NN	O	23	NMOD	0
23	individuals	individual	I-NP	NNS	O	21	PMOD	-1
24	.	.	O	.	O	16	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	reference	reference	I-NP	NN	O	3	NMOD	-1
3	intervals	interval	I-NP	NNS	O	16	SUB	-1
4	for	for	B-PP	IN	O	3	NMOD	-1
5	serum	serum	B-NP	NN	O	6	NMOD	-1
6	IL-8	IL-8	I-NP	NN	B-protein	9	NMOD	-1
7	and	and	O	CC	O	9	NMOD	-1
8	urine	urine	B-NP	NN	O	9	NMOD	-1
9	IL-8	IL-8	I-NP	NN	B-protein	4	PMOD	-1
10	corrected	correct	B-VP	VBN	O	9	NMOD	-1
11	by	by	B-PP	IN	O	10	VMOD	-1
12	creatinine	creatinine	B-NP	NN	O	11	PMOD	-1
13	(	(	O	(	O	15	DEP	-1
14	Cr	Cr	B-NP	NN	O	15	DEP	-1
15	)	)	O	)	O	12	NMOD	-1
16	were	be	B-VP	VBD	O	0	ROOT	-1
17	15.9-430.3	15.9-430.3	B-NP	CD	O	18	NMOD	-1
18	pg/mL	pg/mL	I-NP	NN	O	22	NMOD	-1
19	and	and	O	CC	O	22	NMOD	-1
20	0.0-28.4	0.0-28.4	B-NP	CD	O	22	NMOD	-1
21	pg/mg	pg/mg	I-NP	NN	O	22	NMOD	-1
22	Cr	Cr	I-NP	NN	O	16	PRD	-1
23	,	,	O	,	O	22	P	-1
24	respectively	respectively	B-ADVP	RB	O	22	NMOD	-1
25	.	.	O	.	O	16	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	concentrations	concentration	I-NP	NNS	O	6	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	urine	urine	B-NP	NN	O	5	NMOD	-1
5	IL-8/Cr	IL-8/Cr	I-NP	NN	O	3	PMOD	-1
6	were	be	B-VP	VBD	O	0	ROOT	-1
7	significantly	significantly	B-ADJP	RB	O	8	AMOD	-1
8	higher	high	I-ADJP	JJR	O	6	PRD	-1
9	in	in	B-PP	IN	O	8	AMOD	-1
10	patients	patient	B-NP	NNS	O	9	PMOD	-1
11	than	than	B-PP	IN	O	8	AMOD	-1
12	in	in	B-PP	IN	O	11	PMOD	-1
13	controls	control	B-NP	NNS	O	12	PMOD	0
14	(	(	O	(	O	25	DEP	-1
15	48.9+/-194.4	48.9+/-194.4	B-NP	CD	O	19	NMOD	-1
16	vs.	vs.	I-NP	IN	O	19	NMOD	-1
17	5.2+/-13.8	5.2+/-13.8	I-NP	CD	O	19	NMOD	-1
18	pg/mg	pg/mg	I-NP	NN	O	19	NMOD	-1
19	Cr	Cr	I-NP	NN	O	21	NMOD	-1
20	,	,	O	,	O	21	P	-1
21	P	P	B-NP	NN	O	25	DEP	-1
22	less	less	B-ADJP	JJR	O	21	NMOD	-1
23	than	than	B-PP	IN	O	22	AMOD	-1
24	0.001	0.001	B-NP	CD	O	23	PMOD	-1
25	)	)	O	)	O	13	NMOD	-1
26	.	.	O	.	O	6	P	-1

1	However	However	B-ADVP	RB	O	4	VMOD	-1
2	,	,	O	,	O	4	P	-1
3	there	there	B-NP	EX	O	4	SUB	-1
4	were	be	B-VP	VBD	O	0	ROOT	-1
5	no	no	B-NP	DT	O	7	NMOD	-1
6	significant	significant	I-NP	JJ	O	7	NMOD	-1
7	differences	difference	I-NP	NNS	O	4	PRD	-1
8	in	in	B-PP	IN	O	4	VMOD	-1
9	serum	serum	B-NP	NN	O	11	NMOD	-1
10	IL-8	IL-8	I-NP	NN	O	11	NMOD	-1
11	concentrations	concentration	I-NP	NNS	O	8	PMOD	-1
12	between	between	B-PP	IN	O	11	NMOD	-1
13	NHL	NHL	B-NP	NN	O	14	NMOD	-1
14	patients	patient	I-NP	NNS	O	16	NMOD	-1
15	and	and	O	CC	O	16	NMOD	-1
16	controls	control	B-NP	NNS	O	12	PMOD	0
17	(	(	O	(	O	24	DEP	-1
18	159.2+/-40.4	159.2+/-40.4	B-NP	CD	O	21	NMOD	-1
19	vs.	vs.	I-NP	IN	O	21	NMOD	-1
20	99.6+/-107.1	99.6+/-107.1	B-NP	CD	O	21	NMOD	-1
21	pg/mL	pg/mL	I-NP	NN	O	23	NMOD	-1
22	;	;	O	:	O	23	P	-1
23	P=0.099	P=0.099	B-NP	NN	O	24	DEP	-1
24	)	)	O	)	O	16	NMOD	-1
25	.	.	O	.	O	4	P	-1

1	Receiver	Receiver	B-NP	NN	O	8	SUB	-1
2	operating	operate	B-VP	VBG	O	1	NMOD	-1
3	characteristic	characteristic	B-ADJP	JJ	O	7	NMOD	-1
4	(	(	O	(	O	6	DEP	-1
5	ROC	ROC	B-NP	NN	O	6	DEP	-1
6	)	)	O	)	O	3	NMOD	-1
7	analysis	analysis	B-NP	NN	O	2	OBJ	-1
8	gave	give	B-VP	VBD	O	0	ROOT	-1
9	0.83	0.83	B-NP	CD	O	11	AMOD	-1
10	and	and	I-NP	CC	O	11	AMOD	-1
11	0.43	0.43	I-NP	CD	O	14	NMOD	-1
12	ROC	ROC	I-NP	NN	O	14	NMOD	-1
13	area	area	I-NP	NN	O	14	NMOD	-1
14	values	value	I-NP	NNS	O	8	OBJ	-1
15	for	for	B-PP	IN	O	8	VMOD	-1
16	urine	urine	B-NP	NN	O	17	NMOD	-1
17	IL-8/Cr	IL-8/Cr	I-NP	NN	O	20	NMOD	-1
18	and	and	O	CC	O	20	NMOD	-1
19	serum	serum	B-NP	NN	O	20	NMOD	-1
20	IL-8	IL-8	I-NP	NN	B-protein	15	PMOD	-1
21	,	,	O	,	O	8	P	-1
22	respectively	respectively	B-ADVP	RB	O	8	VMOD	-1
23	.	.	O	.	O	8	P	-1

1	There	There	B-NP	EX	O	2	SUB	-1
2	was	be	B-VP	VBD	O	0	ROOT	-1
3	no	no	B-NP	DT	O	4	NMOD	-1
4	correlation	correlation	I-NP	NN	O	2	PRD	-1
5	between	between	B-PP	IN	O	4	NMOD	-1
6	the	the	B-NP	DT	O	10	NMOD	-1
7	serum	serum	I-NP	NN	O	10	NMOD	-1
8	and	and	I-NP	CC	O	10	NMOD	-1
9	urine	urine	I-NP	NN	O	10	NMOD	-1
10	concentrations	concentration	I-NP	NNS	O	5	PMOD	-1
11	of	of	B-PP	IN	O	10	NMOD	-1
12	IL-8	IL-8	B-NP	NN	B-protein	15	NMOD	-1
13	and	and	O	CC	O	15	NMOD	-1
14	clinical	clinical	B-NP	JJ	O	15	NMOD	-1
15	variables	variable	I-NP	NNS	O	11	PMOD	-1
16	,	,	O	,	O	2	P	-1
17	the	the	B-NP	DT	O	19	NMOD	-1
18	only	only	I-NP	JJ	O	19	NMOD	-1
19	exception	exception	I-NP	NN	O	20	SUB	-1
20	being	be	B-VP	VBG	O	2	VMOD	-1
21	the	the	B-NP	DT	O	24	NMOD	-1
22	international	international	I-NP	JJ	O	24	NMOD	-1
23	prognostic	prognostic	I-NP	JJ	O	24	NMOD	-1
24	index	index	I-NP	NN	O	20	PRD	-1
25	(	(	O	(	O	27	DEP	-1
26	IPI	IPI	B-NP	NN	B-protein	27	DEP	-1
27	)	)	O	)	O	24	NMOD	-1
28	,	,	O	,	O	24	P	-1
29	which	which	B-NP	WDT	O	24	NMOD	-1
30	showed	show	B-VP	VBD	O	29	SBAR	-1
31	a	a	B-NP	DT	O	33	NMOD	-1
32	marginal	marginal	I-NP	JJ	O	33	NMOD	-1
33	correlation	correlation	I-NP	NN	O	30	OBJ	-1
34	with	with	B-PP	IN	O	33	NMOD	-1
35	urine	urine	B-NP	NN	O	37	NMOD	-1
36	IL-8/Cr	IL-8/Cr	I-NP	NN	O	37	NMOD	-1
37	levels	level	I-NP	NNS	O	34	PMOD	-1
38	(	(	O	(	O	40	DEP	-1
39	P=0.07	P=0.07	B-NP	NN	O	40	DEP	-1
40	)	)	O	)	O	37	NMOD	-1
41	.	.	O	.	O	2	P	-1

1	This	This	B-NP	DT	O	2	NMOD	-1
2	study	study	I-NP	NN	O	3	SUB	-1
3	indicated	indicate	B-VP	VBD	O	0	ROOT	-1
4	that	that	B-SBAR	IN	O	3	VMOD	-1
5	urine	urine	B-NP	NN	O	7	NMOD	-1
6	IL-8/Cr	IL-8/Cr	I-NP	NN	O	7	NMOD	-1
7	levels	level	I-NP	NNS	O	8	SUB	-1
8	might	might	B-VP	MD	O	4	SBAR	-1
9	be	be	I-VP	VB	O	8	VC	-1
10	useful	useful	B-ADJP	JJ	O	9	PRD	-1
11	as	as	B-PP	IN	O	10	AMOD	-1
12	a	a	B-NP	DT	O	14	NMOD	-1
13	diagnostic	diagnostic	I-NP	JJ	O	14	NMOD	-1
14	marker	marker	I-NP	NN	O	11	PMOD	-1
15	of	of	B-PP	IN	O	14	NMOD	-1
16	NHL	NHL	B-NP	NN	O	15	PMOD	-1
17	.	.	O	.	O	3	P	-1

